Compare Abbott Laboratories (ABT) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Nasdaq100 ETF — how do they compare? Abbott Laboratories trades at $110.71 (market cap $187.95B), while Nasdaq100 ETF trades at $725.03. The key difference: Abbott Laboratories pays a 2.32% dividend while Nasdaq100 ETF pays none, and Nasdaq100 ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | QQQ | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | — |
52-Week High | $136.62 | $746.16 |
52-Week Low | $82.57 | $558.34 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
QQQ trades at $725.43, up 0.64% with a bullish technical signal from moving averages. The ETF shows strong institutional interest with Ferguson Shapiro LLC increasing its position by 2,685.7% according to SEC filings. Recent news highlights Nasdaq's tech-led rally potential in H2 2026, with momentum and Fed liquidity supporting further upside according to Zacks Investment Research.
Outlook remains positive given historical performance and current technical strength, though RSI levels suggest potential near-term consolidation. Key risks include ETF expense ratios and market volatility, while opportunities lie in continued tech sector leadership and institutional accumulation patterns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
